A home-based oncology model using clear bagging is transformational for practices, protecting Medicare reimbursement and provider control, while lowering costs for patients, providers and payers
|Videos|July 16, 2015
Jennifer Malin, MD, Discusses Challenges Facing Payers in Medical Oncology
Jennifer Malin, MD, medical director for oncology at Anthem, explains how both physicians and payers struggle with the high cost of some cancer treatment drugs.
Advertisement
Jennifer Malin, MD, medical director for oncology at Anthem, believes that both physicians and payers struggle with the high cost of some cancer treatment drugs, which is a large part of what medical oncology focuses on.
She says it’s hard to weigh the high cost of the therapy in a manner that doesn’t put the risk on the physician.
“I think that’s the challenge, trying to figure out how to support the care of these complex patients, not incentivizing use of expensive therapies that aren’t going to improve outcomes but also not putting physicians at risk for a $10,000 a month therapy,” Dr Malin says.
Advertisement
Related to this article
Facing steep 2027 cost increases, employers are narrowing obesity drug coverage, while direct-to-employer models let them cap what they spend.
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.
Norah Terrault, MD, MPH, on why few diagnosed patients reach HCV cure and how primary care test-and-treat can close the gap.
An analysis of AccessHope case reviews found that experts recommended changes in more than 80% of cases. About half were implemented, saving a median of $18,636 per case.
Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.
At an AJMC® Stakeholder Interchange in Los Angeles, leukemia specialists described a region where hospital formularies push menin inhibitor starts into the clinic, emergency department (ED) physicians may not recognize differentiation syndrome, and capitated insurance contracts steer some patients with acute myeloid leukemia away from academic centers.
Advertisement
Advertisement
Trending on AJMC
1
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
2
Enlicitide LDL-C Lowering Holds Across Risk Levels Up to 2 Years
3
FDA Approves First Plasmid DNA-Based Immunotherapy for Adults With RRP
4
HS Comorbidities: Navigating Metabolic, Bowel, Cardiovascular, and Mental Health Risks
5